SEC EDGARSEP 91 min read$BNGO

Luderer Albert purchased $5K of BNGO (indirect holdings)

Luderer Albert (Interim Chief Executive) purchased 4,000 indirectly-held shares of Bionano Genomics, Inc. (BNGO) at $1.21 on 2026-09-04.

Original reporting

SEC EDGAR · Luderer Albert

Published Sep 9, 2026, 8:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 9, 2026, 8:36 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$BNGO

Neutral

high confidence

Mentioned

$BNGO

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$BNGONeutralLow

Why it matters

The transaction adds a modest stake for the CEO but is unlikely to move the stock.

Market read

Low relevance; primarily a compliance disclosure with minimal trading impact.

What to watch

Potential upcoming product milestones or financing events not disclosed yet.

Relevance 3/10Novelty 6/10Timing: filed today

Background

SEC Form 4 filing by Bionano Genomics' interim CEO reporting a modest open‑market purchase.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$BNGONeutralHigh confidence

Context

Form 4 shows interim CEO Albert Luderer bought 4,000 shares at $1.2112, increasing his stake to 8,000 shares.

Expected impact

Likely negligible price movement.

Evidence & confidence

Purchase size (~$5K) is small relative to market cap; no material change in ownership.

Market effects

Sector

None; insider activity does not affect broader genomics sector.

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider buys can signal confidence; monitor for future accumulation.

Key entities

Company
Bionano Genomics, Inc.
NASDAQ‑listed genomics sequencing company.
Person
Luderer Albert
Interim Chief Executive and insider.

Read at source ← All news

SEP 14

$TYRAHighAI 8/10

Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains

Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.

rttnews.com3 min

SEP 14

$BNGOMed

Bionano: OGM Studies Reveal High-Risk Genomic Alterations Missed By Standard Cytogenetics

Bionano Genomics (BNGO) reported that three studies showed its optical genome mapping (OGM) technology identified high-risk genomic alterations in blood cancers, often missed by standard methods. OGM detected significant variants in 15.9% of MDS cases and 46% of cytogenetically normal AML samples, impacting survival rates. The studies suggest OGM could improve risk stratification and treatment planning. BNGO shares are up 2.05% at $1.24.

rttnews.com3 min

AUG 17

$BNGOMedAI 8/10

Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript

Bionano Genomics (BNGO) reported Q2 2026 revenue of $8.2 million, up 21% year over year, driven by higher OGM consumables sales. Flow cell sales rose 27% to 9,219 units, though the company said it is backordered due to manufacturing constraints. Installed base was 397 systems. Adjusted gross margin was 53%. Full-year 2026 revenue guidance is $31 million to $33 million.

fool.com6 min

AUG 12

$BNGOMed

Bionano Genomics, Inc. Q2 2026 Earnings Call Summary

Bionano Genomics reported Q2 2026 results on an earnings call, citing 30% YoY consumables growth and record 53% adjusted gross margin from higher adoption and efficiency. Full-year 2026 revenue guidance was raised to $31M-$33M. Flow-cell backorders and manufacturing constraints are expected to ease by Q4 2026. Software revenue fell 16% YoY.

yahoo.com7 min

AUG 10

$BNGOHigh

Bionano Genomics, Inc. (BNGO): Results of Operations and Financial Condition

Bionano Genomics, Inc. (BNGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bionano Reports Second Quarter 2026 Results and Provides a Business Update Conference call today, August 10, 2026, at 4:30 PM ET SAN DIEGO, August 10, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarte

SEC EDGAR 8-K6 min

SEP 23

$CRWDLow

Sentonas Michael sold $11.6M of CRWD

Sentonas Michael (PRESIDENT) sold 49,863 shares of CrowdStrike Holdings, Inc. (CRWD) at an average of $231.74 ($231.61–$242.64, $11.56M total) across 3 trades on 2026-09-21.

SEC EDGAR1 min